reMYND

Executive Summary

reMYND is a Belgian biotechnology company focused on developing first-in-class oral therapies for neurodegenerative diseases, particularly Alzheimer's and Huntington's disease. Founded in 2008 and based in Leuven, the company leverages its deep expertise in neuroscience to target disease-modifying mechanisms such as tau aggregation and synaptic dysfunction. In addition to its drug development pipeline, reMYND operates a Contract Research Organization (CRO) that provides in-vivo proof-of-concept testing services to major pharmaceutical clients using proprietary mouse models. This dual revenue stream provides a financial buffer and validates the company's scientific platform. Despite being private with no disclosed funding rounds, reMYND has sustained operations through CRO revenues and likely grant funding. Its lead programs remain in preclinical or early clinical stages, with no publicly available trial data. The company's focus on oral small molecules offers potential advantages in patient compliance and distribution over injectable biologics, particularly in Alzheimer's where there is high unmet need. However, the lack of recent disclosed milestones or partnerships makes it difficult to assess near-term progress.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1 trial for lead Alzheimer's candidate40% success
• 2026New partnership or licensing deal for the CRO services or pipeline50% success
• 2026Disclosure of preclinical data for Huntington's disease program30% success